, We also thank Franck Morschhauser from the Centre Hospitalier Régional Universitaire de Lille in Lille, France, for his contributions

J. Brechbiel, P. , K. Covino, and P. , Chrysalis Medical Communications

J. Timmerman, Advisory board member and/or consultant for

K. /. Celgene and . Gilead, Partner Therapeutics, and TeneoBio; research funding from Bristol-Myers Squibb, Kite/Gilead, Merck, and Spectrum Pharmaceuticals

C. Herbaux, Personal fees from AbbVie and Roche

V. Ribrag, ;. Msd, B. Squibb, . Epizyme, . Nanostring et al., Advisory board member and/or consultant for

R. Houot-;-novartis, C. Janssen, /. Kite, and . Gilead, Consultant for Bristol-Myers Squibb

S. Neelapu, Advisory board member and/or consultant for Kite

M. Gilead, . Celgene, U. Novartis, . Therapeutics, P. Pfizer et al., Cell Medica

/. Research-funding-from-kite, . Gilead, B. Merck, . Squibb, . Cellectis et al.,

T. Logan-;-abraxis, . Acceleron, . Amgen, . Argos, . Astrazeneca et al., Advisory board member and/or consultant for Prometheus; research funding from Abbott

I. Lossos, Advisory board member for Seattle Genetics and Janssen Scientific; personal fees from Verastem

W. Urba, Advisory board member for AstraZeneca; research funding from Bristol-Myers Squibb

G. Salles, Advisory board member/symposia participant for

B. Amgen, . Squibb, . Abbvie, . Janssen, . Merck et al.,

C. Jacobson, Consultant for Kite, Novartis, Celgene, Humanigen, Pfizer, and Precision BioSciences

C. Carpio, Personal fees from Takeda; non-financial support from Takeda

D. Lathers,

Y. Liu, Former employee of Bristol-Myers Squibb

J. Neely, Employee and stock owner of Bristol-Myers Squibb

S. Suryawanshi, Employee and stock owner of Bristol-Myers Squibb

Y. Koguchi, Research funding from Bristol-Myers Squibb, Shimadzu Corporation, and Tesaro

R. Levy-;-corvus, . Quadriga, . Beigene, . Gigagen, . Teneobio et al., Dragonfly, Innate Pharma, Abpro, Apexigen, Nohla, Spotlight, Forty Seven Inc, xCella, Immunocore, and Walking Fish; research funding from Pfizer, Bristol-Myers Squibb, and Pharmacyclics. REFERENCES 1. NCCN Clinical Practice Guidelines in Oncology. B-Cell Lymphomas. Version 1. 2019. National Comprehensive Cancer Network, Scientific advisory board for Five Prime

M. Roschewski, L. M. Staudt, and W. H. Wilson, Diffuse large B-cell lymphoma-treatment approaches in the molecular era, Nat Rev Clin Oncol, vol.11, issue.1, pp.12-23, 2014.

A. Galaznik, R. Huelin, and M. Stokes, Systematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, Future Sci OA, vol.4, issue.7, p.322, 2018.

J. O. Armitage, R. D. Gascoyne, M. A. Lunning, and F. Cavalli, Non-Hodgkin lymphoma, Lancet, vol.390, pp.298-310, 2017.

K. Wudhikarn and B. K. Link, Comparative effectiveness research in follicular lymphoma: current and future perspectives and challenges, J Comp Eff Res, vol.3, issue.1, pp.95-107, 2014.

C. Casulo, M. Byrtek, and K. L. Dawson, Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study, J Clin Oncol, vol.33, issue.23, pp.2516-2522, 2015.

A. Freedman and . Follicular, update on diagnosis and management, Am J Hematol, vol.93, issue.2, pp.296-305, 2018.

, Opdivo (nivolumab)

, Bristol-Myers Squibb Company, 2019.

, Keytruda (pembrolizumab)

S. M. Ansell, S. A. Hurvitz, and P. A. Koenig, Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma, Clin Cancer Res, vol.15, issue.20, pp.6446-6453, 2009.

S. M. Ansell, M. C. Minnema, and P. Johnson, Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study, J Clin Oncol, vol.37, issue.6, pp.481-489, 2019.

W. Ding, B. Laplant, and T. E. Witzig, PD-1 blockade with pembrolizumab in relapsed low grade non-Hodgkin lymphoma, Blood, vol.130, p.4055, 2017.

D. Capece, D. Verzella, M. Fischietti, F. Zazzeroni, and A. E. , Targeting costimulatory molecules to improve antitumor immunity, J Biomed Biotechnol, p.926321, 2012.

C. Chester, M. F. Sanmamed, J. Wang, and I. Melero, Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies, Blood, vol.131, issue.1, pp.49-57, 2018.

A. Yonezawa, S. Dutt, C. Chester, J. Kim, and H. E. Kohrt, Boosting cancer immunotherapy with anti-CD137 antibody therapy, Clin Cancer Res, vol.21, issue.14, pp.3113-3120, 2015.

N. H. Segal, T. F. Logan, and F. S. Hodi, Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody, Clin Cancer Res, vol.23, issue.8, pp.1929-1936, 2017.

A. Palazon, A. Teijeira, and I. Martinez-forero, Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes, Cancer Res, vol.71, issue.3, pp.801-811, 2011.

D. S. Vinay and B. S. Kwon, 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy, BMB Rep, vol.47, issue.3, pp.122-129, 2014.

R. Houot, M. J. Goldstein, and H. E. Kohrt, Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion, Blood, vol.114, issue.16, pp.3431-3438, 2009.

N. H. Segal, M. Sharma, and D. Le, Assessing the potential for enhanced antibody-dependent cell-mediated cytotoxicity by combining the CD137 antibody urelumab with rituximab or cetuximab in patients with refractory lymphoma or select advanced solid tumors, J Immunother Cancer, vol.4, issue.1, p.267, 2016.

E. Massarelli, N. H. Segal, and V. Ribrag, Clinical safety and efficacy assessment of the CD137 agonist urelumab alone and in combination with nivolumab in patients with hematologic and solid tumor malignancies, J Immunother Cancer, vol.4, issue.1, p.7, 2016.

. Clinicaltrials and . Gov, , 2020.

B. D. Cheson, B. Pfistner, and M. E. Juweid, Revised response criteria for malignant lymphoma, J Clin Oncol, vol.25, issue.5, pp.579-586, 2007.

J. Zhang, K. Song, and J. Wang, S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity, Oncoimmunology, vol.7, issue.4, p.1296996, 2018.

T. Bartkowiak, A. R. Jaiswal, and C. R. Ager, Activation of 4-1BB on liver myeloid cells triggers hepatitis via an interleukin-27-dependent pathway, Clin Cancer Res, vol.24, issue.5, pp.1138-1151, 2018.

. Rituxan,

. South, , 2019.

B. Coiffier, C. Haioun, and N. Ketterer, Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study, Blood, vol.92, issue.6, pp.1927-1932, 1998.

A. Gopal, R. Levy, and R. Houot, A phase I study of utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in combination with rituximab in patients with CD20+ non-Hodgkin?s lymphoma, Hematol Oncol, vol.35, issue.2, p.267, 2017.

D. T. Chu, N. D. Bac, and K. H. Nguyen, An update on anti-CD137 antibodies in immunotherapies for cancer, Int J Mol Sci, vol.20, issue.8, p.1822, 2019.

M. Compte, S. L. Harwood, and I. G. Munoz, A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity, Nat Commun, vol.9, issue.1, p.4809, 2018.

X. Qi, F. Li, and Y. Wu, Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcgammaR affinity, Nat Commun, vol.10, issue.1, p.2141, 2019.

C. Claus, C. Ferrara, and W. Xu, Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy, Sci Transl Med, vol.11, issue.496, p.5989, 2019.